This stock remains an attractive choice for dividend-focused investors seeking a balance of income and stability in the healthcare space. With a forward dividend yield of 3.08%, it stands well above the industry average of 1.4%, offering a reliable income stream that is both competitive and sustainable. Supported by a nearly five-decade history of uninterrupted dividend growth and a manageable payout ratio of 47%, the dividend is secure and designed to weather shifting market conditions. For investors who prioritize consistency, the company’s combination of yield strength and safety underscores why it has been reaffirmed in the Quality Dividends Portfolio.
Operating as one of the largest players in the medical devices industry, this company benefits from its global scale and diverse product portfolio across cardiovascular, surgical, neurological, and diabetes care. Industry trends remain favorable, with aging populations, rising chronic disease prevalence, and continued demand for advanced medical technologies providing long-term tailwinds. Recent growth has been fueled by breakthrough innovations, such as advanced cardiovascular treatments and next-generation diabetes monitoring solutions, which have driven double-digit growth in select business units. At the same time, challenges such as margin pressures, manufacturing scale-up costs, and tariff headwinds highlight the execution risks that come with managing a global portfolio of complex technologies.
Despite these risks, the company’s size, liquidity, and R&D commitment position it to remain a leader in innovation while delivering dependable dividends to shareholders. For investors seeking stability with exposure to one of the most essential industries in the world, this stock offers a compelling mix of income and defensive characteristics.
Read the full analysis to see why it continues to earn its place in the Quality Dividends Portfolio and what investors should expect from its long-term outlook.
